Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C22H26ClNO4 |
Molecular Weight | 403.899 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CCOC(=O)COC1=CC2=C(CC[C@@H](C2)NC[C@H](O)C3=CC=CC(Cl)=C3)C=C1
InChI
InChIKey=RDJQCOBTKKAQAH-FPOVZHCZSA-N
InChI=1S/C22H26ClNO4/c1-2-27-22(26)14-28-20-9-7-15-6-8-19(11-17(15)12-20)24-13-21(25)16-4-3-5-18(23)10-16/h3-5,7,9-10,12,19,21,24-25H,2,6,8,11,13-14H2,1H3/t19-,21-/m0/s1
Molecular Formula | C22H26ClNO4 |
Molecular Weight | 403.899 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 2 / 2 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://adisinsight.springer.com/drugs/800001600Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1976401 | https://www.ncbi.nlm.nih.gov/pubmed/14584972
Sources: http://adisinsight.springer.com/drugs/800001600
Curator's Comment: Description was created based on several sources, including
https://www.ncbi.nlm.nih.gov/pubmed/1976401 | https://www.ncbi.nlm.nih.gov/pubmed/14584972
Amibegron (SR 58611A or SR 58611) is a highly selective agonist for atypical beta3-adrenoceptors. It stimulates neuronal activity in a specific area of the prefrontal cortex and also inhibits intestinal motility. Amibegron was in phase III trials worldwide for the treatment of depression and generalised anxiety disorder but development of the product was discontinued in 2008. Amibegron has been tested for its potential as a treatment for irritable bowel syndrome.
Originator
Approval Year
PubMed
Title | Date | PubMed |
---|---|---|
In vitro inhibition of intestinal motility by phenylethanolaminotetralines: evidence of atypical beta-adrenoceptors in rat colon. | 1990 Aug |
|
Antidepressant profile in rodents of SR 58611A, a new selective agonist for atypical beta-adrenoceptors. | 1992 Aug 25 |
|
Stimulation of the beta3-Adrenoceptor as a novel treatment strategy for anxiety and depressive disorders. | 2008 Feb |
|
Confirmation of antidepressant potential of the selective beta3 adrenoceptor agonist amibegron in an animal model of depression. | 2008 Jun |
|
Implication of beta3-adrenoceptors in the antidepressant-like effects of amibegron using Adrb3 knockout mice in the chronic mild stress. | 2010 Jan 20 |
Patents
Sample Use Guides
This eight week double-blind phase III trial compared the efficacy of paroxetine with two fixed doses of amibegron (175mg or 350mg q12) in treating the symptoms of depression (NCT00385307).
In 24 healthy obese volunteers, amibegron 60 and 180 mg/day tid for 6 days and a single dose on day 7 was safe and well tolerated.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7957612
Amibegron (SR 58611A or SR 58611) increased cyclic AMP levels in membrane homogenates from rat interscapular brown adipose tissue with an EC50 of 20 nM. This compound also stimulated glycerol release from the brown fat cells, with an EC50 of 11 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sun Dec 18 21:03:29 UTC 2022
by
admin
on
Sun Dec 18 21:03:29 UTC 2022
|
Record UNII |
PDQ3ME68U3
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Code | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C48149
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
CHEMBL1193948
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
3035442
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
8687
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
UU-11
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
AMIBEGRON
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
DB05395
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
PDQ3ME68U3
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
C77932
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
C076252
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
121524-08-1
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY | |||
|
DTXSID6047361
Created by
admin on Sun Dec 18 21:03:30 UTC 2022 , Edited by admin on Sun Dec 18 21:03:30 UTC 2022
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
TARGET -> AGONIST |
SHORT-ACTING
|
||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |